MedTrace Logo

Dynamic Monitoring of HER2 and ctDNA Specific Mutations in Patients With Recurrent or Metastatic Breast Cancer by Digital PCR

NCT03947736 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2019-05-14

No results posted yet for this study

Summary

This was a prospective, single-center clinical study. The study was designed to investigate the relationship between plasma HER2 amplification or specific mutations abundance and clinical response in patients with recurrent or metastatic breast cancer.

Conditions

  • Recurrent or Metastatic Breast Cancer

Interventions

DIAGNOSTIC_TEST

cfDNA was detected by dPCR

Without drug intervention, the patient's peripheral blood was collected and cfDNA was extracted for digital PCR detection.

Sponsors & Collaborators

  • Questgenomics

    collaborator OTHER

  • Chinese Academy of Medical Sciences

    lead OTHER

Principal Investigators

  • Dr. yuan, Prof · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-17
Primary Completion
2020-12-31
Completion
2021-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03947736 on ClinicalTrials.gov